美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

亞盛醫藥

41.04

+0.54131.34%

成交量：2.07萬

成交額：84.65萬

市值：38.24億

市盈率：-55.79

高：41.40

開：41.20

低：40.60

收：40.50

52周最高：48.45

52周最低：16.50

股本：9,316.78萬

流通股本：7,158.28萬

量比：1.70

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：40.86

市盈率(LYR):-55.79

資料載入中...

總覽公司新聞公告

亞盛醫藥6月18日成交額為87.38萬美元

港股異動 | 亞盛醫藥-B(06855)再漲超4% Lisaftoclax有望打開R/R AML在美國及海外的潛在增長空間

港股異動 | 亞盛醫藥-B(06855)漲超4%再創新高原創1類新藥奧雷巴替尼等品種13項研究進展在EHA年會展示

亞盛醫藥6月16日成交額為18.98萬美元

亞盛醫藥多項研究亮相，耐立克®治療Ph+ ALL潛力明顯|直擊EHA 2025

亞盛醫藥6月13日成交額為8.99萬美元

亞盛醫藥6月11日成交額為27.41萬美元

中金：升亞盛醫藥目標價至69港元 APG-2575數據亮眼

【2025 EHA】亞盛醫藥核心產品耐立克®和APG-2575等13項進展入選2025年歐洲血液學協會年會

亞盛醫藥6月9日成交額為127.30萬美元

亞盛醫藥盤中漲超10%股價續創年內新高 Lisaftoclax best-in-class潛力進一步驗證

亞盛醫藥第二款大藥蓄勢出海

ASCO2025重點公司簡評(三)：亞盛醫藥

浦银国际证券有...

亞盛醫藥6月5日成交額為4.58萬美元

亞盛醫藥，下一顆“重磅炸彈”呼之欲出

亞盛醫藥6月3日成交額為52.60萬美元

亞盛醫藥-B(06855)Lisaftoclax ASCO數據進一步驗證Best-in-class潛力，公司股價持續向上突破

亞盛醫藥6月2日成交額為49.84萬美元

亞盛醫藥5月30日成交額為40.13萬美元

亞盛醫藥上漲5.91%，報25.87美元/股，總市值22.54億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":41.04,"timestamp":1757361600000,"preClose":40.4987,"halted":0,"volume":20650,"delay":0,"floatShares":71582800,"shares":93167803,"eps":-0.735552,"marketStatus":"盤前交易","change":0.5413,"latestTime":"09-09 06:11:11 EDT","open":41.2,"high":41.4,"low":40.6,"amount":846476.6031,"amplitude":0.019754,"askPrice":45.04,"askSize":100,"bidPrice":30.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.06,"postHourTrading":{"tag":"盘后","latestPrice":41.04,"preClose":41.04,"latestTime":"16:10 EDT","volume":2,"amount":82.12,"timestamp":1757362203755},"volumeRatio":1.7043578555986694},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":1.7043578555986694,"shares":93167803,"dividePrice":0,"high":41.4,"amplitude":0.019754,"preClose":40.4987,"low":40.6,"week52Low":16.5,"pbRate":"40.86","psRate":"69.66","week52High":48.45,"institutionHeld":0,"latestPrice":41.04,"eps":-0.735552,"divideRate":0,"volume":20650,"delay":0,"ttmEps":-0.735552,"open":41.2,"prevYearClose":17.25,"prevWeekClose":40.4987,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":42.47,"twentyDayClose":41.95,"sixtyDayClose":29.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743825600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-08","current":-23.478386,"percent":0.980392,"low":-76.454813,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"high":-21.702816,"avg":-42.462654,"sd":14.204425,"marketCap":3817512539.24},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-08","current":-23.478386,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"marketCap":3817512539.24}],"updateTime":1757410727136},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544182958","title":"亞盛醫藥6月18日成交額為87.38萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544182958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544182958?lang=zh_tw&edition=fundamental","pubTime":"2025-06-19 09:15","pubTimestamp":1750295715,"startTime":"0","endTime":"0","summary":"美东时间2025年6月18日，亚盛医药成交额为87.38万美元，成交额较昨日增加559.85%，当日成交量为2.47万股。亚盛医药于2025年6月18日涨13.4%，报35.88美元，该股过去5个交易日涨20.61%，年初至今涨108.0%，过去60日涨89.14%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-18|87.38万|559.85%|2.47万|#|2025-06-17|13.24万|-30.22%|4195.00|#|2025-06-16|18.98万|111.17%|5911.00|#|2025-06-13|8.99万|-86.07%|2838.00|#|2025-06-12|64.50万|135.37%|2.04万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619091533a7117a3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619091533a7117a3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2544182946","title":"港股異動 | 亞盛醫藥-B(06855)再漲超4% Lisaftoclax有望打開R/R AML在美國及海外的潛在增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2544182946","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544182946?lang=zh_tw&edition=fundamental","pubTime":"2025-06-18 11:36","pubTimestamp":1750217792,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B再涨超4%，截至发稿，涨4.31%，报65.4港元，成交额1.88亿港元。消息面上，亚盛于2025 ASCO大会以口头报告形式展示了Lisaftoclax联用在美国和澳洲人群包含AMLMDS在内的恶性髓系肿瘤数据，其中Venetoclax耐药R/RAML/MPAL人群显示出的31.8%ORR令人惊喜。浦银国际认为，若后续能在更大样本量下Venetoclax耐药R/RAML人群持续显示不错的疗效数据，Lisaftoclax有望打开R/RAML在美国及海外的潜在增长空间。该行认为，APG-2575R/RAML数据亮眼，展现出克服维奈克拉抗药性的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","BK1161","06855","BK4139"],"gpt_icon":0},{"id":"2544124980","title":"港股異動 | 亞盛醫藥-B(06855)漲超4%再創新高 原創1類新藥奧雷巴替尼等品種13項研究進展在EHA年會展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2544124980","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544124980?lang=zh_tw&edition=fundamental","pubTime":"2025-06-17 09:44","pubTimestamp":1750124675,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B早盘涨超4%，高见66.3港元，再创上市新高。截至发稿，涨4.11%，报65.8港元，成交额5632.33万港元。消息面上，6月16日，亚盛医药发布公告，公司原创1类新药奥雷巴替尼（耐立克）和EED抑制剂APG-5918等品种的13项研究进展已在2025年欧洲血液学协会年会上展示。该行认为，APG-2575 R/R AML数据亮眼，展现出克服维奈克拉抗药性的潜力。鉴于维奈克拉尚未核准1L MDS，此适应症竞争格局良好，建议关注临床开展情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1241f583e82227963a979cc1445c279","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1161","BK1574"],"gpt_icon":0},{"id":"2544987671","title":"亞盛醫藥6月16日成交額為18.98萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544987671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544987671?lang=zh_tw&edition=fundamental","pubTime":"2025-06-17 09:15","pubTimestamp":1750122914,"startTime":"0","endTime":"0","summary":"美东时间2025年6月16日，亚盛医药成交额为18.98万美元，成交额较昨日增加111.17%，当日成交量为5911.00股。亚盛医药于2025年6月16日涨1.97%，报32.13美元，该股过去5个交易日涨7.53%，年初至今涨86.26%，过去60日涨65.62%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-16|18.98万|111.17%|5911.00|#|2025-06-13|8.99万|-86.07%|2838.00|#|2025-06-12|64.50万|135.37%|2.04万|#|2025-06-11|27.41万|-57.75%|9162.00|#|2025-06-10|64.86万|-49.05%|2.16万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617091535a4ad2a73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617091535a4ad2a73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2543670770","title":"亞盛醫藥多項研究亮相，耐立克®治療Ph+ ALL潛力明顯|直擊EHA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2543670770","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543670770?lang=zh_tw&edition=fundamental","pubTime":"2025-06-16 09:31","pubTimestamp":1750037460,"startTime":"0","endTime":"0","summary":"该研究结果表明，OVP方案在新诊断Ph+ ALL患者中实现早期高CMR率，并呈现显著的低毒性反应且耐受性良好，有望成为一线治疗的新选择。该研究结果表明，在复发或持续MRD阳性的Ph+ ALL患者中，奥雷巴替尼联合 INO的组合具有较深的分子学反应和良好的耐受性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4710646_ZH10646_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1571399168.USD","BK4139","LU0985320562.USD","06855","BK1161","LU1699723380.USD","BK4588","BK4533","BK1574","LU2355687059.USD","AAPG","BK4585","ALL","BK4107"],"gpt_icon":0},{"id":"2543651870","title":"亞盛醫藥6月13日成交額為8.99萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543651870","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543651870?lang=zh_tw&edition=fundamental","pubTime":"2025-06-14 09:15","pubTimestamp":1749863713,"startTime":"0","endTime":"0","summary":"美东时间2025年6月13日，亚盛医药成交额为8.99万美元，成交额较昨日减少86.07%，当日成交量为2838.00股。亚盛医药于2025年6月13日跌1.59%，报31.51美元，该股过去5个交易日涨11.03%，年初至今涨82.67%，过去60日涨62.42%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614091526a4a8734d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614091526a4a8734d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2542554748","title":"亞盛醫藥6月11日成交額為27.41萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542554748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542554748?lang=zh_tw&edition=fundamental","pubTime":"2025-06-12 09:15","pubTimestamp":1749690913,"startTime":"0","endTime":"0","summary":"美东时间2025年6月11日，亚盛医药成交额为27.41万美元，成交额较昨日减少57.75%，当日成交量为9162.00股。亚盛医药于2025年6月11日跌0.5%，报29.75美元，该股过去5个交易日涨5.16%，年初至今涨72.46%，过去60日涨51.17%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612091533a70458e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612091533a70458e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2542737120","title":"中金：升亞盛醫藥目標價至69港元 APG-2575數據亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2542737120","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542737120?lang=zh_tw&edition=fundamental","pubTime":"2025-06-11 13:31","pubTimestamp":1749619877,"startTime":"0","endTime":"0","summary":"中金发布研报称，维持亚盛医药-b(06855)“跑赢行业”评级，目标价上调25.5%至69港元。亚盛医药近日在美国临床肿瘤学会(ASCO)年会上口头报告了Bcl-2抑制剂APG-2575(lisaftoclax)合并阿扎胞苷针对髓系恶性肿瘤的Ib/II期研究数据，并更新了MDM2-p53抑制剂APG-115(alrizomadlin)治疗晚期腺样囊性癌(ACC)或其它实体瘤患者的II期临床研究资料。该行认为，APG-2575R/R AML数据亮眼，展现出克服维奈克拉抗药性的潜力。鉴于维奈克拉尚未核准1L MDS，此适应症竞争格局良好，建议关注临床开展情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611133453a70325fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611133453a70325fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APG","AAPG"],"gpt_icon":0},{"id":"2542366048","title":"【2025 EHA】亞盛醫藥核心產品耐立克®和APG-2575等13項進展入選2025年歐洲血液學協會年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2542366048","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542366048?lang=zh_tw&edition=fundamental","pubTime":"2025-06-10 09:17","pubTimestamp":1749518220,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州 2025年6月10日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，涉及公司原创1类新药奥雷巴替尼、Bcl-2抑制剂APG-2575、EED抑制剂APG-5918等重磅品种的13项研究进展将在2025年6月12日至15日于意大利米兰举行的2025年欧洲血液学协会年会上公布，其中包括1项口头报告，及多项壁报展示和线上发表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4706661_ZH06661_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","LU1923622291.USD","LU2125909916.SGD","LU2125909759.SGD","BK4129","APG","BK1161","AAPG","BK4139","BK1574"],"gpt_icon":0},{"id":"2542835032","title":"亞盛醫藥6月9日成交額為127.30萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542835032","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542835032?lang=zh_tw&edition=fundamental","pubTime":"2025-06-10 09:15","pubTimestamp":1749518114,"startTime":"0","endTime":"0","summary":"美东时间2025年6月9日，亚盛医药成交额为127.30万美元，成交额较昨日增加621.55%，当日成交量为4.32万股。亚盛医药于2025年6月9日涨5.29%，报29.88美元，该股过去5个交易日涨18.48%，年初至今涨73.22%，过去60日涨60.39%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-09|127.30万|621.55%|4.32万|#|2025-06-06|17.64万|285.42%|6294.00|#|2025-06-05|4.58万|-83.02%|1632.00|#|2025-06-04|26.95万|-48.76%|9489.00|#|2025-06-03|52.60万|5.53%|1.92万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610091526a701524d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610091526a701524d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2542871162","title":"亞盛醫藥盤中漲超10%股價續創年內新高 Lisaftoclax best-in-class潛力進一步驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2542871162","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542871162?lang=zh_tw&edition=fundamental","pubTime":"2025-06-09 10:52","pubTimestamp":1749437520,"startTime":"0","endTime":"0","summary":"亚盛医药-B股价盘中涨超10%创年内新高，因Lisaftoclax潜力获进一步验证。该公司在ASCO年会公布其治疗肿瘤临床研究进展，且自与武田合作以来，股价累计涨幅达260%，市值突破190亿，2024年营收激增342%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609110535951420c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609110535951420c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2542887511","title":"亞盛醫藥第二款大藥蓄勢出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2542887511","media":"药智网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542887511?lang=zh_tw&edition=fundamental","pubTime":"2025-06-09 10:01","pubTimestamp":1749434501,"startTime":"0","endTime":"0","summary":"亚盛医药自去年年中与武田就奥雷巴替尼达成授权合作以来，股价便开启强劲上涨通道。在奥雷巴替尼的授权成功之后，亚盛医药的下一个重磅候选药物——新型Bcl-2抑制剂APG-2575，登场了。从研发进度看，亚盛医药凭借更早的NDA申报时间和更靠前的审批状态，有望率先实现国产Bcl-2抑制剂零的突破，成为全球第二款上市药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609100616a6ffc955&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609100616a6ffc955&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK4139","AAPG"],"gpt_icon":0},{"id":"2542871918","title":"ASCO2025重點公司簡評(三)：亞盛醫藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2542871918","media":"浦银国际证券有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542871918?lang=zh_tw&edition=fundamental","pubTime":"2025-06-09 00:00","pubTimestamp":1749398400,"startTime":"0","endTime":"0","summary":"亚盛于2025 ASCO 大会以口头报告形式展示了Lisaftoclax 联用在美国和澳洲人群包含AML MDS 在内的恶性髓系肿瘤数据，其中Venetoclax耐药R/R AML/MPAL 人群显示出的31.8% ORR 令人惊喜。管理层表示，目前计划将Ventoclax 耐药群体进一步扩大临床样本量至40-50 例患者，若数据积极，后续或有望展开美国R/R AML关键性试验。绝大多数不良事件可控制、可恢复、可耐受。管理层表示，若后续中国数据能够重复先前美国研究的积极疗效，公司将与监管部门进一步探讨后续注册临床研究可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","AAPG","06855"],"gpt_icon":0},{"id":"2541167000","title":"亞盛醫藥6月5日成交額為4.58萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541167000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541167000?lang=zh_tw&edition=fundamental","pubTime":"2025-06-06 09:15","pubTimestamp":1749172514,"startTime":"0","endTime":"0","summary":"美东时间2025年6月5日，亚盛医药成交额为4.58万美元，成交额较昨日减少83.02%，当日成交量为1632.00股。亚盛医药于2025年6月5日跌1.13%，报27.97美元，该股过去5个交易日涨10.34%，年初至今涨62.14%，过去60日涨47.21%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-05|4.58万|-83.02%|1632.00|#|2025-06-04|26.95万|-48.76%|9489.00|#|2025-06-03|52.60万|5.53%|1.92万|#|2025-06-02|49.84万|24.20%|2.01万|#|2025-05-30|40.13万|360.88%|1.63万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606091526a49c2540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606091526a49c2540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2540603213","title":"亞盛醫藥，下一顆“重磅炸彈”呼之欲出","url":"https://stock-news.laohu8.com/highlight/detail?id=2540603213","media":"制药界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540603213?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 15:20","pubTimestamp":1749021659,"startTime":"0","endTime":"0","summary":"以亚盛医药为例，2024年，其首个成功上市的小分子药物、具备全球“BIC”潜力的奥雷巴替尼，达成一笔总金额超过90亿元的对外BD交易。作为在这轮创新药的“寒冬”中率先成功破局的行业领军企业之一，亚盛医药距离自己的第二颗“重磅炸弹”横空出世的关键时刻，已经越来越接近。亚盛医药，已经站在了一个超过200亿美元的全新市场的入口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604152426a49975b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604152426a49975b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","AAPG","BK1574","06978"],"gpt_icon":1},{"id":"2540408159","title":"亞盛醫藥6月3日成交額為52.60萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540408159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540408159?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 09:15","pubTimestamp":1748999715,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，亚盛医药成交额为52.60万美元，成交额较昨日增加5.53%，当日成交量为1.92万股。亚盛医药于2025年6月3日涨10.03%，报27.75美元，该股过去5个交易日涨7.47%，年初至今涨60.87%，过去60日涨39.24%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-03|52.60万|5.53%|1.92万|#|2025-06-02|49.84万|24.20%|2.01万|#|2025-05-30|40.13万|360.88%|1.63万|#|2025-05-29|8.71万|-59.87%|3487.00|#|2025-05-28|21.70万|-51.49%|8779.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091524a6f966c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091524a6f966c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2540744516","title":"亞盛醫藥-B(06855)Lisaftoclax ASCO數據進一步驗證Best-in-class潛力，公司股價持續向上突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2540744516","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540744516?lang=zh_tw&edition=fundamental","pubTime":"2025-06-03 13:46","pubTimestamp":1748929608,"startTime":"0","endTime":"0","summary":"在此背景下，Lisaftoclax最新研究成果以口头报告形式亮相今年ASCO年会，无疑是全球业界关注的焦点。此项全球多中心研究入组患者逾百人，数据显示Lisaftoclax联合阿扎胞苷的耐受性良好并已显示初步疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","BK1161","AAPG","BK4139"],"gpt_icon":0},{"id":"2540712461","title":"亞盛醫藥6月2日成交額為49.84萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540712461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540712461?lang=zh_tw&edition=fundamental","pubTime":"2025-06-03 09:15","pubTimestamp":1748913313,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，亚盛医药成交额为49.84万美元，成交额较昨日增加24.20%，当日成交量为2.01万股。亚盛医药于2025年6月2日涨3.36%，报25.22美元，该股过去5个交易日跌4.76%，年初至今涨46.2%，过去60日涨29.73%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-02|49.84万|24.20%|2.01万|#|2025-05-30|40.13万|360.88%|1.63万|#|2025-05-29|8.71万|-59.87%|3487.00|#|2025-05-28|21.70万|-51.49%|8779.00|#|2025-05-27|44.74万|-16.10%|1.74万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603091522a6f7c730&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603091522a6f7c730&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2539209252","title":"亞盛醫藥5月30日成交額為40.13萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539209252","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539209252?lang=zh_tw&edition=fundamental","pubTime":"2025-05-31 09:15","pubTimestamp":1748654115,"startTime":"0","endTime":"0","summary":"美东时间2025年5月30日，亚盛医药成交额为40.13万美元，成交额较昨日增加360.88%，当日成交量为1.63万股。亚盛医药于2025年5月30日跌3.75%，报24.4美元，该股过去5个交易日跌4.54%，年初至今涨41.45%，过去60日涨25.32%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-30|40.13万|360.88%|1.63万|#|2025-05-29|8.71万|-59.87%|3487.00|#|2025-05-28|21.70万|-51.49%|8779.00|#|2025-05-27|44.74万|-16.10%|1.74万|#|2025-05-23|53.32万|75.73%|2.04万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531091523a49389a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531091523a49389a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2539261631","title":"亞盛醫藥上漲5.91%，報25.87美元/股，總市值22.54億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539261631","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539261631?lang=zh_tw&edition=fundamental","pubTime":"2025-05-29 22:50","pubTimestamp":1748530234,"startTime":"0","endTime":"0","summary":"5月29日，亚盛医药盘中上涨5.91%，截至22:50，报25.87美元/股，成交6.31万美元，总市值22.54亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前,耐立克已被成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/29225050752019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":172,"code":"91000000","status":"200"}]}}